UBS Group’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$79M Buy
670,329
+321,941
+92% +$45M 0.01% 1226
2025
Q4
$57.1M Sell
348,388
-108,541
-24% -$17M 0.01% 1479
2025
Q3
$61.1M Buy
456,929
+161,731
+55% +$19.6M 0.01% 1422
2025
Q2
$36.7M Buy
295,198
+54,124
+22% +$6.89M 0.01% 1793
2025
Q1
$30.7M Buy
241,074
+52,263
+28% +$8.04M 0.01% 1936
2024
Q4
$27.2M Buy
188,811
+135,808
+256% +$19.5M 0.01% 2008
2024
Q3
$7.89M Sell
53,003
-20,894
-28% -$3M ﹤0.01% 2603
2024
Q2
$9.32M Sell
73,897
-7,851
-10% -$1.23M ﹤0.01% 2264
2024
Q1
$15M Buy
81,748
+46,917
+135% +$8.93M ﹤0.01% 1926
2023
Q4
$6.26M Buy
34,831
+5,311
+18% +$827K ﹤0.01% 2532
2023
Q3
$4.69M Sell
29,520
-60,646
-67% -$9.91M ﹤0.01% 2636
2023
Q2
$12.8M Buy
90,166
+34,282
+61% +$5.5M ﹤0.01% 1796
2023
Q1
$9.41M Buy
55,884
+10,101
+22% +$1.8M ﹤0.01% 1938
2022
Q4
$7.75M Buy
45,783
+17,526
+62% +$3.18M ﹤0.01% 2107
2022
Q3
$5.29M Buy
28,257
+2,560
+10% +$540K ﹤0.01% 2301
2022
Q2
$4.17M Sell
25,697
-3,200
-11% -$506K ﹤0.01% 2523
2022
Q1
$5.43M Sell
28,897
-26,017
-47% -$4.94M ﹤0.01% 2454
2021
Q4
$14.5M Buy
54,914
+5,866
+12% +$1.58M ﹤0.01% 1817
2021
Q3
$14.2M Buy
49,048
+8,258
+20% +$2.12M ﹤0.01% 1771
2021
Q2
$8.14M Sell
40,790
-8,969
-18% -$1.74M ﹤0.01% 2215
2021
Q1
$9.67M Sell
49,759
-6,837
-12% -$1.4M ﹤0.01% 1980
2020
Q4
$10.8M Buy
56,596
+1,598
+3% +$291K ﹤0.01% 1783
2020
Q3
$8.12M Buy
54,998
+22,623
+70% +$3.23M ﹤0.01% 1793
2020
Q2
$4M Sell
32,375
-9,374
-22% -$1.1M ﹤0.01% 2225
2020
Q1
$4.03M Sell
41,749
-96,630
-70% -$9.33M ﹤0.01% 2116
2019
Q4
$12.8M Sell
138,379
-10,312
-7% -$866K ﹤0.01% 1724
2019
Q3
$11.4M Buy
148,691
+120,004
+418% +$10.5M ﹤0.01% 1667
2019
Q2
$2.47M Sell
28,687
-15,886
-36% -$1.08M ﹤0.01% 2960
2019
Q1
$2.63M Sell
44,573
-112,361
-72% -$6.46M ﹤0.01% 2748
2018
Q4
$8.28M Buy
156,934
+129,049
+463% +$7.57M ﹤0.01% 1718
2018
Q3
$1.55M Buy
27,885
+125
+0.5% +$6.44K ﹤0.01% 3451
2018
Q2
$1.31M Sell
27,760
-31,170
-53% -$1.28M ﹤0.01% 3547
2018
Q1
$2.13M Buy
58,930
+48,051
+442% +$1.69M ﹤0.01% 3085
2017
Q4
$395K Sell
10,879
-20,625
-65% -$747K ﹤0.01% 4456
2017
Q3
$1.21M Buy
31,504
+1,179
+4% +$49.4K ﹤0.01% 3551
2017
Q2
$1.26M Buy
30,325
+18,989
+168% +$722K ﹤0.01% 3415
2017
Q1
$399K Sell
11,336
-11,282
-50% -$357K ﹤0.01% 4201
2016
Q4
$697K Buy
22,618
+11,673
+107% +$361K ﹤0.01% 3866
2016
Q3
$330K Sell
10,945
-225
-2% -$6.79K ﹤0.01% 4200
2016
Q2
$305K Sell
11,170
-3,145
-22% -$80.4K ﹤0.01% 4251
2016
Q1
$384K Sell
14,315
-20,574
-59% -$503K ﹤0.01% 3977
2015
Q4
$987K Buy
34,889
+21,934
+169% +$633K ﹤0.01% 3418
2015
Q3
$361K Buy
12,955
+1,690
+15% +$61.1K ﹤0.01% 4167
2015
Q2
$465K Buy
11,265
+2,953
+36% +$108K ﹤0.01% 4185
2015
Q1
$252K Sell
8,312
-4,955
-37% -$129K ﹤0.01% 4696
2014
Q4
$263K Buy
+13,267
New +$297K ﹤0.01% 4779

Other funds holding RGEN

UBS Group's RGEN Position: Q1 2026 in Review

UBS Group increased its Repligen (RGEN) stake by 92% in Q1 2026, buying an estimated $45M and bringing the position to 670,329 shares worth $79M. The position accounts for 0.01% of the portfolio, ranked #1226.

UBS Group first reported a position in RGEN in Q4 2014 and has held it in 46 quarters since. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

  • UBS Group held 670,329 shares of Repligen worth $79M as of Q1 2026.
  • UBS Group bought 321,941 Repligen shares in Q1 2026, an estimated $45M.
  • Repligen made up 0.01% of UBS Group's portfolio in Q1 2026, its #1226 holding.
  • UBS Group first reported a position in Repligen in Q4 2014 and has held it in 46 quarters since.
  • 441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.